Jyong Biotech (MENS) is trading down at $2.16 (-0.73%), as of the latest quote. It operates in the Health Care sector.
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$2.80M | −$2.06M | −$2.61M |
| Net income | −$4.40M | −$3.02M | −$4.67M |
| EPS (diluted) | −$0.06 | −$0.04 | −$0.06 |
| Balance sheet | |||
| Cash and equivalents | $1.74M | $101.0K | $1.18M |
| Total assets | — | $6.37M | $20.8M |
| Total liabilities | — | $42.9M | $45.7M |
| Long-term debt | — | — | $2.12M |
| Shareholders' equity | −$34.1M | −$36.5M | −$24.9M |
| Cash flow | |||
| Operating cash flow | −$2.60M | −$3.62M | −$3.04M |
From Jyong Biotech's 20-F filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. Filings on SEC EDGAR →
No recent news mentioning Jyong Biotech in our feed yet.